Ekso Bionics Holdings Inc (OQ:EKSO)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 101 GLACIER POINT, SUITE A
SAN RAFAEL CA 94901
Tel: 1-212-8671768
Website: https://ir.eksobionics.com
IR: See website
<
Key People
Scott G. Davis
Chief Executive Officer, Director
Jerome Wong
Chief Financial Officer, Corporate Secretary
Jason C. Jones
Chief Operating Officer
Business Overview
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The Company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
Financial Overview
For the fiscal year ended 31 December 2023, Ekso Bionics Holdings Inc revenues increased 42% to $18.3M. Net loss increased 1% to $15.2M. Revenues reflect EksoHealth segment increase of 50% to $17.7M, United States segment increase of 91% to $12.5M, Other Americas segment increase of 96% to $495K. Higher net loss reflects FV Adjustments of Financial Investments decrease from $1.3M (income) to $133K (expense).
Employees: 70 as of Mar 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $19.11M as of Dec 31, 2023
Annual revenue (TTM): $18.28M as of Dec 31, 2023
EBITDA (TTM): -$13.41M as of Dec 31, 2023
Net annual income (TTM): -$15.20M as of Dec 31, 2023
Free cash flow (TTM): -$12.21M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,903,128 as of Mar 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.